Emerging in the landscape of excess body fat treatment, retatrutide presents a different strategy. Beyond many current medications, retatrutide operates as a twin agonist, at once engaging both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic hormone (GIP) binding sites. This dual stimulation encourages various helpful effects, such